*:Co-first author; #:Co-corresponding author
1. Xiaowei Sha, Jiaqian Li, Yunlong Fang, Jingjie Feng, Yasong Feng, Jing Wang Yang Si, Feng Li, Shan Cheng, Wei Ding. Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866. BMC Cancer. 2025; 25(1):1174.
2. Zhicheng Ge, Jing Wang, Libing He, Meng Zhao, Yang Si, Siyuan Chang, Guoyan Zhang, Shan Cheng, Wei Ding. Reconstruction of cancer marker analysis with holistic anatomical precision implicates heterogeneity development during breast tumor progression. Discov Oncol. 2024, 15(1):564.
3. Huan Niu, Meng Zhao, Jing Huang, Jing Wang, Yang Si, Shan Cheng, Wei Ding. UHMK1-dependent phosphorylation of Cajal body protein coilin alters 5-FU sensitivity in colon cancer cells. Cell Commun Signal, 2022, 20(1):18. IF:6.153
4. Mengtian Cui, Qingfang Zhao, Jing Wang, Yang Si, Shan Cheng#, Wei Ding#. ATF6-mediated unfolded protein response facilitates AAV2 transduction by releasing the suppression of AAV receptor on ER stress. J Virol, 2022, 96(3): e0110321. IF: 5.078
5. Jing Huang, Mu Hu, Huan Niu, Jing Wang, Yang Si, Shan Cheng#, Wei Ding#. Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels. BMC Cancer, 2021, 21(1):750. IF:4.372
6. Jing Niu, Rui-Qi Gao, Meng-Tian Cui, Chen-Guang Zhang, Shen-Tao Li, Shan Cheng#, Wei Ding#. Suppression of TCAB1 expression induced cellular senescence by lessening proteasomal degradation of p21 in cancer cells. Cancer Cell Int, 2021, 21(1): 26. IF: 5.45
7. Siyuan Chang, Jing Huang, Huan Niu, Jing Wang, Yang Si, Zhigang Bai, Shan Cheng , Wei Ding. Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5‑FU treatment. Cancer Cell Int, 2020, 20:452.
8. Fenglian Yang*; Mu Hu*; Siyuan Chang, Jing Huang, Yang Si, Jinghui Wang, Shan Cheng, Wenguo Jiang. Alteration in the sensitivity to crizotinib by Na+/H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers, BMC Cancer, 2020, 20(1):202.